Article
Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM.
Drugs - 1 Dec 2023
Tewkesbury Daniel, Jones Andrew M, Bright-Thomas Rowland, Cratchley Alyn, Hanley Karen Piper, Wyatt Judith, Athwal Varinder, Barry Peter J
Abstract excerpt
BACKGROUND: The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (E/T/I) has been associated with substantial multisystem benefits for people with CF eligible for therapy. In a minority, tolerance has been limited by hepatic toxicity. It is unknown whether there may be particular risk factors for significant drug-induced elevation in transaminases....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.